Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897025 | 0.85 | MAPT (0.32) | ALDH1A1GAAMAPT | |
| SCHEMBL14687494 | 0.82 | — | — | |
| SCHEMBL5896833 | 0.81 | CYP3A4 (0.38) | ALDH1A1GAAMAPTCYP3A4 | |
| SCHEMBL5897164 | 0.81 | — | — | |
| SCHEMBL1224812 | 0.74 | ACHE (0.36) | ALDH1A1 | |
| SCHEMBL7030626 | 0.74 | GAA (0.39) | AKT1ALDH1A1GAAMAPTCYP3A4 | |
| SCHEMBL6408114 | 0.73 | RAPGEF4 (0.33) | RAPGEF4ALDH1A1 | |
| SCHEMBL19009972 | 0.71 | HSD11B1 (0.30) | RAPGEF4 | |
| SCHEMBL14688051 | 0.68 | CYP1A2 (0.42) | ALDH1A1ALOX15 | |
| SCHEMBL14688271 | 0.66 | MAPT (0.36) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294193-B2 | Compound, and flavor composition and/or fragrance composition containing same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-05-21 | — | — | US | disclosed |
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9796678-B2 | Method for manufacturing optically active compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| EP-3153492-A1 | NOVEL COMPOUND AND FRAGRANCE COMPOSITION CONTAINING SAME | Takasago International Corporation (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-20170088503-A1 | NOVEL COMPOUND, AND FLAVOR COMPOSITION AND/OR FRAGRANCE COMPOSITION CONTAINING SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-03-30 | — | — | US | disclosed |
| EP-2774908-B1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO PERFUMERY CO LTD (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-1277748-B1 | Process for producing optically active y-Butyrolactone | TAKASAGO PERFUMERY CO LTD (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403262-A1 | Process for producing optically active alpha butyrolactone | Takasago International Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-6608214-B2 | Hydrogenating optically active 4-substituted oxy-3-hydroxy-butyrate followed by simultaneous deprotection and ring closure; economic and efficient synthesis | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-06-05 | — | — | US | disclosed |
| EP-1277748-A1 | Process for producing optically active y-Butyrolactone | Takasago International Corporation (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6342644-B1 | MULTISTAGE PROCESS OF HYDROGENATION WITH PHOSPHINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-29 | — | — | US | disclosed |
| US-20020007094-A1 | Method for producing 1-menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-1153908-A2 | Method for producing 1-menthol | Takasago International Corporation (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | AKT1 3546/4885RAPGEF4 1836/4885ALDH1A1 6/4885 |
| US-10294193-B2 | Compound, and flavor composition and/or fragrance composition containing same | FZD7, TAS1R1, TAS2R5 | AKT1 2516/4885RAPGEF4 4845/4885ALDH1A1 83/4885 |
| US-20030105341-A1 | Process for producing optically active gamma-butyrolactone | HSD17B10, HSD17B1, HSD17B12 | AKT1 1884/4885RAPGEF4 4095/4885ALDH1A1 77/4885 |
| US-20020007094-A1 | Method for producing 1-menthol | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PHOSPHO1 | AKT1 3575/4885RAPGEF4 492/4885ALDH1A1 1768/4885 |
| US-20170022162-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND | C9, C5, PRMT7 | AKT1 1038/4885RAPGEF4 2770/4885ALDH1A1 296/4885 |
| US-20170088503-A1 | NOVEL COMPOUND, AND FLAVOR COMPOSITION AND/OR FRAGRANCE COMPOSITION CONTAINING SAME | FZD7, TAS2R5, TAS2R40 | AKT1 2698/4885RAPGEF4 4798/4885ALDH1A1 122/4885 |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | ADH1C, ADH1A, ADH5 | AKT1 403/4885RAPGEF4 1030/4885ALDH1A1 22/4885 |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | FNTB, FNTA, LSS | AKT1 307/4885RAPGEF4 449/4885ALDH1A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.